Contrasting factors associated with COVID-19-related ICU admission and death outcomes in hospitalised patients by means of Shapley values

Massimo Cavallaro[1,2*], Haseeb Moiz[3], Matt J. Keeling[1,2], Noel D. McCarthy[1,3*]

[1]The Zeeman Institute for Systems Biology & Infectious Disease Epidemiology Research, University of Warwick, Coventry, CV4 7AL, United Kingdom.

[2]School of Life Sciences and Mathematics Institute, University of Warwick, Coventry, CV4 7AL, United Kingdom.

[3]Warwick Medical School, University of Warwick, Coventry, CV4 7AL, United Kingdom.

*To whom correspondence should be addressed: M.Cavallaro@warwick.ac.uk and Noel.Mccarthy@tcd.ie

Abstract

Identification of those at greatest risk of death due to the substantial threat of COVID-19 can benefit from novel approaches to epidemiology that leverage large datasets and complex machine-learning models, provide data-driven intelligence, and guide decisions such as intensive-care unit admission (ICUA). The objective of this study is two-fold, one substantive and one methodological: substantively to evaluate the association of demographic and health records with two related, yet different, outcomes of severe COVID-19 (viz., death and ICUA); methodologically to compare interpretations based on logistic regression and on gradient-boosted decision tree (GBDT) predictions interpreted by means of the Shapley impacts of covariates. Very different association of some factors, e.g., obesity and chronic respiratory diseases, with death and ICUA may guide review of practice. Shapley explanation of GBDTs identified varying effects of some factors among patients, thus emphasising the importance of individual patient assessment. The results of this study are also relevant for the evaluation of complex automated clinical decision systems, which should optimise prediction scores whilst remaining interpretable to clinicians and mitigating potential biases.

Author summary

The design is a retrospective cohort study of 13954 in-patients of ages ranging from 1 to 105 year (IQR: 56, 70, 81) with a confirmed diagnosis of COVID-19 by 28th June 2020. This study used multivariable logistic regression to generate odd ratios (ORs) multiply adjusted for 37 covariates (comorbidities, demographic, and others) selected on the basis of clinical interest and prior findings. Results were supplemented by gradient-boosted decision tree (GBDT) classification to generate Shapley values in order to evaluate the impact of the covariates on model output for all patients. Factors are differentially associated with death and ICUA and among patients.

Deaths due to COVID-19 were associated with immunosuppression due to disease (OR 1.39, 95% CI 1.10-1.76), type-2 diabetes (OR 1.31, 95% CI 1.17-1.46), chronic respiratory disease

(OR 1.19, 95% CI 1.05-1.35), age (OR 1.56/10-year increment, 95% CI 1.52-1.61), and male
sex (OR 1.54, 95% CI1.42-1.68). Associations of ICUA with some factors differed in direction
(e.g., age, chronic respiratory disease). Self-reported ethnicities were strongly but variably
associated with both outcomes.

GBDTs had similar performance (ROC-AUC, ICUA 0.83, death 0.68 for GBDT; 0.80 and 0.68
for logistic regression). We derived importance scores based on Shapley values which were
consistent with the ORs, despite the underlying machine-learning model being intrinsically
different to the logistic regression. Chronic heart disease, hypertension, other
comorbidities, and some ethnicities had Shapley impacts on death ranging from positive to
negative among different patients, although consistently associated with ICUA for all.
Immunosuppressive disease, type-2 diabetes, and chronic liver and respiratory diseases had
positive impacts on death with either positive or negative on ICUA.

We highlight the complexity of informing clinical practice and public-health interventions.
We recommend that clinical support systems should not only predict patients at risk, but
also yield interpretable outputs for validation by domain experts.

Introduction

COVID-19, due to SARS-CoV-2 betacoronavirus, emerged in Wuhan, China in late 2019 and
has spread globally. It can cause severe complications of pneumonia, acute respiratory
distress syndrome, sepsis, and septic shock[1]. It has, as of October 24, 2020, infected over 42
million people and killed over 1.1 million people[2]. Certain patient subsets, such as the
elderly and those with comorbidities, are at an increased risk of severe outcomes from
COVID-19 such as admission to intensive care units, respiratory distress requiring
mechanical ventilation, and death[3,4].

Clinicians can use predictive factors to prioritize patients at higher risk of clinical
deterioration and public health authorities can use them to target public health
interventions. Identifying factors associated with severe disease has been described as an
urgent research priority. Several studies have sought to identify factors predicting poor
outcome following COVID-19 infection[5,6] and assist clinician decision making[7–9]. A
traditional method such as logistic regression can infer the odd ratios (ORs) of the outcome
in the presence of a risk factor. Modern machine-learning technologies, widely
implemented during the COVID-19 pandemic, can handle more complex patient data types,
offer greater generality, and produce more accurate predictions than the previous methods,
but at the cost of losing transparency and interpretability[10].

Surveillance systems support these analyses. The COVID-19 Hospitalization in England
Surveillance System (CHESS), a UK system distributed by Public Health England (PHE) and
adapted from the UK severe influenza surveillance system, collects extensive data on
patients admitted to hospital, including known comorbidities and important demographic
information (such as age, sex, and ethnicity)[11]. This large national dataset reduces
limitations inherent in small cohorts, enabling more reliable identification of associations.
We performed analyses on this dataset using logistic regression and a more general
machine-learning model (the gradient-boosted decision tree, GBDT), which generated
interpretable predictions by means of the Shapley additive explanation, a technique

thatmitigates the interpretability issue in machine-learning outputs. For different
applications of this technique to COVID-19 research see, e.g., references [12,13]. Through these
methods, we demonstrated the extent to which pre-existing conditions differentially
predicted death and intensive care unit (ICU) admission. Some factors affected both
similarly but others proved to be protective for one while increasing the risk for the other,
or showed very different effect sizes. We also identified variation of effects among patients.
These results may be useful to clinicians assessing hospitalized patients with COVID-19. They
may also provide a greater context or benchmark for individuals evaluating or interpreting
complex automated clinical decision systems designed to identify those most at-risk.

Materials and methods

Description of cohort and outcomes

We studied a cohort of 13954 patients of which 8947 patients survived and 5007 died after
contracting COVID-19. 5758 were admitted to ICUs, of whom 3483 were discharged after
treatment, and 2275 died. The dataset includes epidemiological data (demographics, risk
factors, and outcomes) on patients with a confirmed diagnosis of COVID-19 by 28th June
2020 who required hospitalization. We included all available chronic and pre-existing
morbid conditions recorded by PHE as potential risk factors, including immunosuppression
due to disease, asthma requiring medication, immunosuppression due to treatment,
neurological conditions, respiratory conditions, obesity, type-1 and type-2 diabetes,
hypertension, heart conditions, renal disease, liver diseases, and other comorbidities[11]. No
acute illnesses or medical conditions were considered. In the CHESS dataset self-defined
ethnicity is categorized according to the Office for National Statistics questionnaires into 17
factors, all included in the study. With 8628 patients, white British was the largest group in
the cohort and therefore chosen as a reference category. 1895 patients did not identify
themselves with any ethnicity and were labelled as "NA". With the exception of age and
admission date, all features were stratified to binary variables. Entries labelled "diabetes"
whose type was unknown and not recorded in the database as "type 1", have been
considered as "type 2". Death and ICU admission were chosen as outcomes. The median age
of this sample was 70 years (IQR 56-81, range 1-105), 59.25% were men and 0.18% had an
unrecorded sex. The prevalence of comorbidities is reported in Table 1 and ethnicity in
Table 2. Cross-correlations between recorded ethnicities and pre-existing conditions are
illustrated in Figure 1.

Statistical analysis

Logistic regression models were used to estimate odd ratios (ORs) of all 37 pre-existing
conditions and demographic factors for both outcomes. Standard errors (SEs) and
confidence intervals (CIs) of the ORs were computed using the Taylor series-based delta
method and the profile likelihood method, respectively, and statistical significance assessed
using the Benjamini-Hochberg (BH) test with false discovery rate set to 0.05[14].

In addition, we applied a "gradient boosted decision tree" (GBDT) machine-learning model
with logistic objective function, as an appropriate machine learning approach. A GBDT
aggregates a large number of weak prediction models, in this case decision trees, into a
robust prediction algorithm, where the presence of many trees mitigates the errors due to a
single-tree prediction. Each individual tree consists of a series of nodes that represent

binary decision splits against one of the input variables, with its final output being
determined by the nodes at the end of the tree (known as leaves). The model was
implemented in the XGBoost library (version 0.81)[23] and depended on a number of hyper-
parameters. To avoid over-fitting, these hyper-parameters were selected by means of
Bayesian optimization of c-statistics using 5-fold cross-validation over the training set[24] with
constant L1-regularisation parameter $\alpha = 0.5$. We used Shapley additive explanation (SHAP)
analysis to understand the result of a GBDT model fit[15,16]. The importance of each feature in
the model output is represented by the so-called Shapley values, introduced in game theory
literature and providing a theoretically justified method for allocation of credit among a
group of players. In the context of machine learning, the same mathematics is used to
allocate the credit for the GBDT prediction among the N features included in the study, for
each of the M patients. The chief output of this approach is a $M \times N$ matrix of Shapley
values ϕ_{ij} where i indicates a patient, $i = 1,2,\ldots,N$, and j is a pre-existing condition or
other patient characteristic, $j = 1,2,\ldots,N$. We also refer to the Shapley value ϕ_{ij} as the
impact of j on the outcome for the patient i. Similar to the logistic regression model, for
each patient i, the trained GBDT model returns a decision value f_i to be interpreted as the
logarithm of the odds that the outcome is poor. The Shapley values are unique allocations of
credit in explaining the decision f_i among all the N features, where for our case, negative
values ($\phi_{ij} < 0$) tip the decision value towards good outcome, while positive values
($\phi_{ij} > 0$) towards bad (i.e., ICU or death). The model output satisfies $f_i = \sum_{j=0}^{N} \phi_{ij}$ (which is
the local accuracy property), where ϕ_{i0} is a bias term. Importantly, it has been
mathematically proven that the Shapley allocation is the only possible one that satisfies two
additional desirable properties, i.e., consistency (if a feature's contribution increases or
stays the same regardless of the other inputs, its Shapley value does not decrease), and
missingness (a zero-valued feature contributes a zero Shapley value)[15–17]. In tree-based
models, the same idea has been extended to allocate the credit to pairs of features, thus
yielding $f_i = \sum_{k=0}^{N} \sum_{j=0}^{N} \Phi_{ijk}$, where the Φ_{ijk}s are referred to as SHAP interaction values[16].
The diagonal term Φ_{ijj} encodes the net effect on the model prediction f_i of a feature j,
stripped of its interactions with the other features $k \neq j$ and is referred to as the SHAP main
effect of j. We used an implementation specific to tree-based models, also referred to as
TreeSHAP, accessible via the XGBoost and SHAP libraries; we refer the reader to
references[15,16] for a more comprehensive discussion and for the implementation details.

Such an approach explains each individual prediction f_i and is therefore referred to as a
local method. In contrast to that, as a complementary *global* method, we consider the so-
called partial dependence plots (PDPs) to show the average effects of age and admission
date on the predicted outcomes, marginalizing over the values of all other features[18].

It is worth comparing this approach with the standard logistic regression. For a patient i with
feature values $\mathbf{X}_i := (x_{i1}, x_{i2}, \ldots, x_{iN})$, the logistic regression and the GPDT models predict
an outcome (here taken to be ICUA or death) with probabilities $p(\mathbf{X}_i)$ and $\tilde{p}(\mathbf{X}_i)$,
respectively. These satisfy

$$\log \frac{p(\mathbf{X}_i)}{1 - p(\mathbf{X}_i)} = \beta_0 + \beta_1 \cdot x_{i1} + \beta_2 \cdot x_{i2} + \cdots + \beta_N \cdot x_{iN}$$

164   and

$$\log \frac{\widetilde{p}\,(\mathbf{X}_i)}{1 - \widetilde{p}\,(\mathbf{X}_i)} =: f_i = \phi_{i0} + \phi_{i1} + \phi_{i2} + \cdots + \phi_{iN},$$

where the coefficients β_j sare maximum-likelihood estimates and the values ϕ_{ij}s are
obtained by means of the TreeSHAP algorithm. To rank the features by their overall
importance, we estimate the slopes $\boldsymbol{\phi}_j\,\mathbf{x}_j^T/(\mathbf{x}_j\mathbf{x}_j^T)$ for each j, where
$\boldsymbol{\phi}_j := \left(\phi_{1j}, \phi_{2j}, \ldots, \phi_{Nj}\right)$ and $\mathbf{x}_j := \left(x_{1j}, x_{2j}, \ldots, x_{Nj}\right)$, thus obtaining a novel feature score
which we refer to as Imp_j and can be directly compared to the coefficient β_j.

All models were fitted to a randomly chosen 90% of data entries, while the remaining
entries were used for validation. Goodness-of-prediction was assessed by means of the c-
statistics of the receiver operating characteristic curve (ROC-AUC) on the validation set, with
bootstrapped 2.5%-97.5% confidence intervals.

Results

Risk factors showed strong associations with both death and ICUA, but the strength and
even direction of these associations differed substantially across these outcomes. From
logistic regression analysis, immunosuppression due to disease (OR 1.39, 95% CI 1.10-1.76),
type-2 diabetes (OR 1.31, 95% CI 1.17-1.46), chronic respiratory disease (OR 1.19, 95% CI
1.05-1.35), age (OR 1.56 for each 10 year age increment, 95% CI 1.51-1.61), and being male
(OR 1.54, 95% CI 1.42-1.68) were strongly associated with deaths due to COVID-19. The
regression was adjusted for other comorbidities including type-1 diabetes, chronic liver
disease, serious mental illness, chronic renal disease, chronic neurological condition, chronic
heart disease, hypertension, obesity and asthma, none of which were significantly
associated with death (BH test). Having any comorbidity other than these was recorded in
the dataset as "other comorbidity" and appeared to be a protective factor (OR death, 0.87,
95% CI 0.79-0.95). Some self-reported ethnicities, compared to white British, were
associated with substantially increased risk of death (e.g., Indian (OR 1.84, 95% CI 1.42-
2.73)) risk of death. Asymptomatic testing was associated with substantially lower risk of
death (OR 0.29, 95% CI 0.18-0.45). The estimated ORs of deaths are detailed in Table 3 and
illustrated in Figure S1.

Among co-morbidities, obesity (OR 3.37, 95% CI 2.90-3.29), serious mental illness (OR 2.57,
95% CI 1.51-4.46), hypertension (OR 1.58, 95% CI 1.42-1.76), asthma (OR 1.51, 95% CI 1.29-
1.77), and "other comorbidity" (OR 1.31, 95% CI 1.19-1.45) were strongly positively
associated with ICU admission (Table 3, Figure S2). Each of these had far weaker or even
negative associations with death. Some features associated with increased risk of death
such as chronic respiratory disease were negatively associated with ICUA (OR 0.83, 95% CI
0.72-0.96). No ethnicity was negatively associated with ICUA compared to white British
although there was substantial variation across these. Other factors associated with ICUA
included immunosuppression due to treatment (OR 1.793, 95% CI 1.41-2.28) and male sex
(OR 1.73, 95% CI 1.58-1.89). Old age (OR 0.76, 95% CI 0.74-0.78 for each 10-year increment),
asymptomatic testing (OR 0.52, 95% CI 0.35-0.74), and pregnancy (OR 0.34, 95% CI 0.20-
0.57) were associated with decreased ICUA. The associations of each predictor with death
and with ICUA are illustrated in Figure 2, highlighting some contrasts in direction and
magnitude while other risk factors appear more consistently associated with the two

outcomes. The overall associations obtained from the GBDT model were consistent with the
logistic model results.

The receiver operating characteristic (ROC) curves for the logistic regression models are
plotted in Figure 3. The ROC-Area Under the Curve (AUC) scores for the logistic regression
classifiers were 0.68 (95% CI 0.65-0.71) and 0.80 (95% CI 0.78-0.82) for death and ICUA
outcome predictions, respectively. Generalized collinearity diagnostics by means of variance
inflation factor (VIF) excluded severe collinearity (VIFs <2, Table 4, see also reference [19]).
The scores of GBDT for classification task were 0.68 (95% CI 0.66-0.71) and 0.83 (95% CI
0.82-0.85) for the death and ICUA outcome predictions, respectively. In addition to outcome
prediction, the GBDT analysis with Shapley value explanations yielded the impact of each
feature on both death and ICUA outcome for each single patient (summarised in Figures S3
and S4).

We contrasted the Shapley values for impacts on death and ICUA in Figure 4. All patients
with obesity, serious mental illness, immunosuppressing treatment, male sex, asymptomatic
admission, and those whose self-reported ethnicity was other black, Indian, black
Caribbean, other Asian, other white, and NA had concordant impacts to death and ICU
admission. In almost all asthma patients, it is possible to appreciate negative impact on
death and positive impact on ICUA. Patients with type-1 diabetes, chronic renal disease, or
chronic neurological disease show positive association with death and negative association
with ICUA outcome, although with very dispersed Shapley value distributions. Upon visual
inspection, the scatter points for chronic liver disease, type-1 diabetes, chronic neurological,
and chronic heart comorbidities show two (or more) clusters with respect to the impact on
death. The hypertension scatter plot displays a neat partition with respect to the impact on
ICUA outcome, showing that this variable was associated with ICUA. Its impact on death is
less clear, with patients having discordant or concordant Shapley values for death. The cases
of type-2 diabetes and chronic respiratory disease appear diametrically opposite to these, as
all patients with such conditions had positive Shapley values for death with qualitatively
different impacts on ICU outcome.

Stratifing on ICUA yields marginally higher ROC-AUC scores (logistic regression 0.69 (95% CI
0.66-0.72), GBDT 0.70 (95% CI 0.67-0.72) compared to death prediction obtained without
ICUA prediction. In fact, ICUA is a very strong predictor of death (OR 2.25, 95% CI 2.04-2.48)
but is markedly correlated to other features (Figure 1). The full results are summarised in
Figures S5 and S6, and Table S1.

The features were ranked according to their median ORs and their importance scores *Imp*
(defined in methods), showing that these two are ordinally associated in both death
(Spearman's ρ=0.47, P=0.005) and ICUA outcomes (Spearman's ρ=0.97, P=13×10^{-22}), as
shown in Figure 5. The explanation model for the GBDT was therefore largely consistent
with the interpretable logistic linear model. The analysis of SHAP main effect also revealed
the *non-linear* relations between outcomes and the age and admission day (Figures 6 and
7). The probability of death rose above 30 years of age. Likelihood of ICU admission
decreased markedly above 60.

Discussion

This cohort study investigated the association between patient characteristics (demographics and comorbidities) and severe outcomes with COVID-19 using a large national dataset in England (the CHESS database). Our findings on many factors were largely consistent with the patterns observed worldwide in studies on patients infected with SARS-CoV-2[20–32]. Both logistic and GBDT models predicted admission to ICU more accurately than death.

Obese patients were approximately 3.4-fold more likely to be admitted to ICU (the strongest association for any co-morbid condition), while the association with mortality was small and non-significant (OR 1.16, BH test). In a US study involving 3615 patients, patients with a body mass index (BMI) between 30 and 35 were 2-fold more likely to reach the ICU and those with a BMI of over 35 were 3-fold more likely, when compared to BMIs of less than 30[20]. These very high levels of ICUA in our and other works, as well as the contrastingly weaker association with COVID-19 mortality, could be explained by clinicians tending to, relatively, over-admit obese patients to ICU. It could reflect ICUA being very effective in reducing mortality in this group and is an important area for further research[33]. Hypertension, and asthma were associated with ICU admission but not death. Others have reported increased risk of severe COVID-19 among asthmatics, with the increase driven only by patients with non-allergic asthma[25]. Hypertension has been associated with severe COVID-19 disease in previous univariable studies but there is no clear evidence that hypertension is an independent risk factor[27].

Black or Asian minority ethnic groups showed higher odds of death and substantially higher odds of ICU admission in our data compared to white British patients. Similar findings to ours have been demonstrated UK-wide. Multivariable analyses from large multi-ethnic cohorts have suggested that Asian and black patients group experienced an excessive level of mortality, hospital admission, and intensive care admission even when differences in age, sex, deprivation, geographical region, and some key comorbidities were taken into account[5,26,28,29]. White Irish ethnicity was non-significantly associated with lower risk of death (OR 0.49, BH test). This finding, adjusted for all covariates, echoes findings in an earlier study comparing death rates standardised for age and region using census data[28]. Chinese ethnicity predicted ICU admission (OR 10.22 with respect to the white British baseline) most strongly, followed by black Caribbean (OR 5.25). For these and other minority groups the association with ICU admission far exceeded that of death. An unrecorded or unknown ethnicity was strongly negatively associated with ICU admission, but not strongly associated with death. This may indicate increased recording of ethnicity on ICU admission, a potential cause of bias in estimating true differences in risk of ICU admission across ethnicities.

Age, type-1 diabetes, and neurological, heart, and respiratory diseases were negatively associated with ICU admission but not death. Age and chronic respiratory disease were strongly positively associated with death. Data gathered across the USA showed that deaths are 90 times higher in the 65-74 age group than the 18-29 age group and 630 times higher in the 85 and older group[34]. This may reflect judgements of limited capacity to benefit from ICU admission due to age and some co-morbidities. Type-2 diabetes is broadly reported to be associated with poor outcome in COVID-19 patients, while studies reporting outcome for

type-1 diabetes are rare[30,31]. A national general practice based analysis in England
demonstrated that both type-1 and type-2 diabetes are associated with increased risk of in-
hospital death with COVID-19[32]. Our multiply adjusted analysis of the CHESS dataset
confirmed that type-2 diabetes had a strong association with mortality (and non-significant
association with ICU admission), while type-1 diabetes' association was positive but not
statistically significant. On the other hand, type-1 diabetes was negatively associated with
ICUA outcome. There is uncertainty regarding the effect of diabetes and glycaemic control
on COVID-19 outcome. Whilst some suggest a 3-fold increase in intensive care admission
and death[22], others found no association between glycaemic control and severe outcome[24].
Potential mechanisms for effects could include hyperinsulinemia or the interaction of SARS-
CoV-2 with ACE2 receptors expressed in pancreatic β cells[30,35].

Male sex was positively and similarly associated with both ICU admission and death. The
increased risk of male deaths is consistent with worldwide data, in which, on average, 1.4-
fold more men than women have died from SARS-CoV2, with some countries reporting
greater than 2-fold male deaths[36]. Increased expression of the ACE2 receptor may occur in
men and has been suggested as a possible explanation for this finding[23]. Asymptomatic
testing and pregnancy demonstrated a strong negative association with both death and ICU
admission. These results were expected in view of NHS trusts undertaking surveillance
swabs for asymptomatic people, including among elective hospital admissions.

Different machine-learning models have been leveraged to predict COVID-19 patients at risk
of sudden deterioration. A study over 162 infected patients in Israel demonstrated that
artificial intelligence may allow accurate risk prediction for COVID-19 patients using three
models (neural networks, random trees, and random forests)[37]; a random forest model was
used over 1987 patients for early prediction of ICU transfer[38]; the GBDT model was
deployed on blood-sample data from 485 patients in Wuhan, China[39]; GBDT models
outperformed conventional early-warning scoring systems for ventilation requirement
prediction over 197 patients[40]; deep learning and ensemble models were reported to
perform well for early warning and triaging in China[9,41]. These models are very complex, but
evidence indicates that mortality predictions can be obtained from more parsimonious
models, upon selecting the most important features, thus facilitating more efficient
implementation of machine-learning in clinical environments[42]. Despite these successes,
prediction models have been found overall to be poorly reported and at high risk of bias in a
systematic review[43]. A comprehensive list of relevant works is out of the scope of this paper,
but it is worth underlining that machine-learning methods typically excel in outcome
prediction but lack ease of interpretation of the result. In this study, we bridged the gap
between performance and interpretability in machine learning for poor outcome
predictions in COVID-19 patients. We trained GBDT models (see methods section) and
extracted not-only their predictions, but also the extent to which each potential risk factor
contributed to the prediction overall (thus permitting comparisons with the more easily-
interpretable logistic regression model) and for each patient. So-called "Shapley values"
quantify such information, as summarised in Figure S3 and S4 for death and ICU
respectively.

Overall, the association of patient features with the final outcome (measured by the SHAP
importance scores *Imp*, see methods and Figure 5) is consistent with the logistic regression
results, although the two models are intrinsically different. Moreover, for each feature, we

derived an individual Shapley value for each patient, allowing us to consider the variation in
effects among patients. As a first example, we discuss interpretation of type-2 diabetes. In
the summary plots of Figures 4, S3, and S4, the red markers correspond to type-2 diabetes
patients and blue to patients without type-2 diabetes. In the summary plot for death
outcome (Figure S3, see also Figure 4), the red and blue markers are grouped into two
distinct clusters. All the type-2 diabetes patients had positive Shapley values, thus showing
that such a comorbidity was always associated with death, while all the other patients had
nearly zero Shapley values. Conversely, in the summary plot for ICUA outcome (Figure S4,
see also Figure 4), the red markers appear scattered. Some T2-diabetes patients had
positive Shapley values (positive association with ICU admission) while others had negative
values (a negative association with ICU admission). The summary plots thus show not only
the overall importance of a potential risk factor, but also its range of effects over the
patients. In this case our interpretation is that although consistently increasing the risk of
death, the presence of type 2 diabetes had more variable impact on decision making around
ICU admission, in some cases apparently adding to the case for admission and in some cases
diminishing it.

Being male was positively associated with both death and ICU admission. Its impacts were
concordant in sign and confined within a narrow range of values. Conversely, for example,
chronic renal disease and immunosuppressive treatment had low impact on predicting
death for some patients, but very high impact for others, perhaps reflecting that these
categories comprise a number of diverse conditions and therapies. Considering ethnicity,
most minority groups were consistently and positively associated with ICUA but the impact
attributed to Pakistani ethnicity were much more variable.

Shapley value analysis of the GBDT model also excels in explaining the nonlinear relations
between covariates and their importance to outcome prediction. In Figure 6A, the predicted
probability of death is shown to increase with age, in part due to increasing presence of
comorbidities which are correlated with increasing age (Figure 1). In fact, the isolated effect
of age (the SHAP main effects for age), illustrated in Figure 6C, shows a sharp rise from age
30 even if it is stripped from the interactions with the other factors. For ICUA, the SHAP
main effect for age abruptly drops and even reverses from the 60th year of age (Figure 7).
The abruptness may suggest an age threshold is being applied in clinical decision making on
ICU admission.

During the first peak of COVID-19 epidemic healthcare services were under variable strain,
and clinical expertise growing over time. Declining in-hospital mortality was observed in
Italy[44] and England[45] during the first pandemic peak. This may reflect a mix of changing
pressure, developing clinical expertise and variable follow up time following admission. We
included the patient's admission day in our models to allow for these effects in adjustment
(logistic regression) and attribution of impact (machine learning). Hospital admission later
than March decreased both death and ICUA. These results mirror the PDPs outlined in
Figures 7 and 8 A-B, showing that a local explanation technique such as the Shapley value
analysis supersedes and is consistent with the global explanation of the PDPs. The
performance gains of the GBDTs here are small, in part due to the fact that all but two
predictors (age and admission date) are binary. Indeed, the logistic model predictions
depend on a linear combination of the predictor values, which is adequate if all the
predictors are binary and the classes are linearly separable. The similarity in the predictive

power for these specific cases should not shadow the other advantages of the GBDTs
(including their greater generality and their ability of detecting non-linearity and variation in
predictive effect).

While all our models had excellent performances, it is worth noting that prediction of ICUA
outcome was significantly better than death alone prediction for both. Including laboratory
test results in the predictor variable may improve death prediction[46].

In conclusion, this study confirms that, in hospitalised patients, the risk of severe COVID-19,
defined as either death or transfer to intensive care unit, is strongly associated with known
demographic factors and comorbidities. We found that the association of these variables
with death was often qualitatively and quantitatively different from their association with
ICU admission. This was consistently derived by means of two different predictive models,
i.e., the standard logistic and the GDBT machine-learning models. The Shapley value
explanation of the latter model also highlights the sometimes variable impact of each factor
for each patient. These results allow an insight into the variable impact of individual risk
factors on clinical decision support systems. We suggest that these should not only grant
the optimal average prediction, but also provide interpretable outputs for validation by
domain experts. Shapley values may also support analytical approaches to address the
problem of characterising the group of patients for whom a prediction is incorrect. This is an
important additional potential area for research and application. Shapley-value analyses
allow clinical interpretation of the results from a complex machine-learning model such as
the GBDT. Using these we have derived importance scores which are consistent with the
better known ORs as an overall assessment of an average effect but can additionally display
the extent to which this average effect is consistent across patients or highly variable among
different patient groups. We recommend the wider adoption of Shapley-value analyses to
support interpretation of ML outputs in clinical decision making given this capacity to
communicate the variation in the effects of predictive variables. These aspects are
particularly valuable to tackle COVID-19, a complex disease that can cause a variety of
symptoms and clinical outcomes, depending on the patients' conditions, and rapidly
overwhelm healthcare systems, thus requiring large-scale automated decision systems.

Acknowledgments

This work was supported by Health Data Research UK, which is funded by the UK Medical
Research Council, EPSRC, Economic and Social Research Council, Department of Health and
Social Care (England), Chief Scientist Office of the Scottish Government Health and Social
Care Directorates, Health and Social Care Research and Development Division (Welsh
Government), Public Health Agency (Northern Ireland), British Heart Foundation and the
Wellcome Trust. MK and NM are affiliated to the National Institute for Health Research
Health Protection Research Units (NIHR HPRUs) in Gastrointestinal Infections and in
Genomics and Enabling Data The views expressed are those of the author(s) and not
necessarily those of the NIHR, the Department of Health and Social Care or Public Health
England.

Competing interests

421 The authors declare no competing interests.

Ethical considerations

Data from the CHESS database were supplied after anonymisation under strict data protection protocols agreed between the University of Warwick and Public Health England. The ethics of the use of these data for these purposes was agreed by Public Health England with the Government's SPI-M(O)/ SAGE committees.

Software and reproducibility

Data management was performed using Python (version 3.7.1) and Pandas (version 0.23.4), with analyses carried out using Python, Scikit-learn (version 0.20.1), and R (version 3.4.3). All codes for data management and analysis are archived online at https://github.com/mcavallaro/CovidC.

Data availability

Data on cases were obtained from the COVID-19 Hospitalisation in England Surveillance System (CHESS) data set that collects detailed data on patients infected with COVID-19. Data on COVID-19 deaths were obtained from Public Health England. These data contain confidential information, with public data deposition non-permissible for socioeconomic reasons. The CHESS data resides with the National Health Service (www.nhs.gov.uk) whilst the death data are available from Public Health England (www.phe.gov.uk).

Contributors

This study was conceived and designed by MC and NDM. MJK acquired the data, which were analysed by MC. MC, HM, and NDM wrote the manuscript, which was critically revised by MC, HM, MJK, and NDM.

References

1. Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J. & Prescott, H. C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA - Journal of the American Medical Association* **324**, 782–793 (2020).

2. WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard.

3. Zhou, Y. *et al*. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. *International Journal of Infectious Diseases* **99**, 47–56 (2020).

4. Xie, J., Tong, Z., Guan, X., Du, B. & Qiu, H. Clinical Characteristics of Patients Who Died of Coronavirus Disease 2019 in China. *JAMA Netw. open* **3**, e205619 (2020).

5. Williamson, E. J. *et al*. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* **584**, 430–436 (2020).

6. McKeigue, P. M. *et al*. Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study. *PLOS Med.* **17**, e1003374 (2020).

7. Clift, A. K. *et al*. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from

coronavirus 19 in adults: national derivation and validation cohort study. *BMJ* **371**, m3731 (2020).

8. Knight, S. R. *et al.* Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical
Characterisation Protocol: development and validation of the 4C Mortality Score. *BMJ* **370**, m3339 (2020).

9. Gao, Y. *et al.* Machine learning based early warning system enables accurate mortality risk prediction for COVID-
19. *Nat. Commun.* (2020). doi:10.1038/s41467-020-18684-2

10. Molnar, C., Casalicchio, G. & Bischl, B. Interpretable Machine Learning -- A Brief History, State-of-the-Art and
Challenges. (2020). doi:Interpretable Machine Learning -- A Brief History, State-of-the-Art and Challenges

11. Letter: COVID-19 Hospitalisation in England Surveillance System (CHESS) – daily reporting. Available at:
https://www.england.nhs.uk/coronavirus/publication/letter-covid-19-hospitalisation-in-england-surveillance-
system-chess-daily-reporting. (Accessed: 6th April 2021)

12. Booth, A. L., Abels, E. & McCaffrey, P. Development of a prognostic model for mortality in COVID-19 infection
using machine learning. *Mod. Pathol.* **34**, 522–531 (2021).

13. Zoabi, Y., Deri-Rozov, S. & Shomron, N. Machine learning-based prediction of COVID-19 diagnosis based on
symptoms. *npj Digit. Med.* **4**, 3 (2021).

14. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple
Testing. *J. R. Stat. Soc. Ser. B* **57**, 289–300 (1995).

15. Lundberg, S. M. & Lee, S.-I. A Unified Approach to Interpreting Model Predictions. *Nips* **16**, 426–430 (2012).

16. Lundberg, S. M. *et al.* From local explanations to global understanding with explainable AI for trees. *Nat. Mach.*
Intell. **2**, 56–67 (2020).

17. Shapley, L. S. *et al.* A VALUE FOR n-PERSON GAMES. in *Contributions to the Theory of Games (AM-28), Volume II*
307–318 (Princeton University Press, 1953).

18. Friedman, J. H. Greedy function approximation: A gradient boosting machine. *Ann. Stat.* **29**, 1189–1232 (2001).

19. Fox, J. & Weisberg, S. *An R companion to applied regression*.

20. Lighter, J. *et al.* Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **71**, 896–897
(2020).

21. Simonnet, A. *et al.* High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
Requiring Invasive Mechanical Ventilation. *Obesity* **28**, 1195–1199 (2020).

22. Riddle, M. C. *et al.* COVID-19 in People with Diabetes: Urgently Needed Lessons from Early Reports. *Diabetes Care*
43, 1378–1381 (2020).

23. Klein, S. L. *et al.* Biological sex impacts COVID-19 outcomes. *PLOS Pathog.* **16**, e1008570 (2020).

24. Cariou, B. *et al.* Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the
CORONADO study. *Diabetologia* **63**, 1500–1515 (2020).

25. Zhu, Z. *et al.* Association of asthma and its genetic predisposition with the risk of severe COVID-19. *J. Allergy Clin.*
Immunol. **146**, 327-329.e4 (2020).

26. Sapey, E. *et al.* Ethnicity and Risk of Death in Patients Hospitalised for COVID-19 Infection: An Observational
Cohort Study in an Urban Catchment Area. *SSRN Electron. J.* (2020). doi:10.2139/ssrn.3588545

27. Shibata, S. *et al.* Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of
Hypertension Task Force on COVID-19. *Hypertension Research* **43**, 1028–1046 (2020).

28. Aldridge, R. W. *et al.* Black, Asian and Minority Ethnic groups in England are at increased risk of death from COVID-

497   19: indirect standardisation of NHS mortality data. *Wellcome Open Res.* **5**, 88 (2020).

498   29.   Alaa, A. M. *et al. Ethnicity and Outcomes of COVID-19 Patients in England.*

499   30.   Apicella, M. *et al.* COVID-19 in people with diabetes: understanding the reasons for worse outcomes. *lancet.*
500   *Diabetes Endocrinol.* **0**, (2020).

501   31.   Drucker, D. J. Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications. *Endocr.*
502   *Rev.* **41**, (2020).

503   32.   Barron, E. *et al.* Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-
504   population study. *Lancet Diabetes Endocrinol.* (2020). doi:10.1016/S2213-8587(20)30272-2

505   33.   Simonnet, A., Chetboun, M., Poissy, J., ... V. R.- & 2020, U. High Prevalence of Obesity in Severe Acute Respiratory
506   Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. *Obesity* **28**, 1994–1994 (2020).

507   34.   Provisional Death Counts for Coronavirus Disease 2019 (COVID-19).

508   35.   The Lancet Diabetes Endocrinology, T. L. D. &. COVID-19 and diabetes: a co-conspiracy? *lancet. Diabetes*
509   *Endocrinol.* **8**, 801 (2020).

510   36.   COVID-19 sex-disaggregated data tracker – Global Health 50/50.

511   37.   Assaf, D. *et al.* Utilization of machine-learning models to accurately predict the risk for critical COVID-19. *Intern.*
512   *Emerg. Med.* 1–9 (2020). doi:10.1007/s11739-020-02475-0

513   38.   Cheng, F.-Y. *et al.* Using Machine Learning to Predict ICU Transfer in Hospitalized COVID-19 Patients. *J. Clin. Med.*
514   **9**, 1668 (2020).

515   39.   Yan, L. *et al.* An interpretable mortality prediction model for COVID-19 patients. *Nat. Mach. Intell.* **2**, 283–288
516   (2020).

517   40.   Burdick, H. *et al.* Prediction of respiratory decompensation in Covid-19 patients using machine learning: The
518   READY trial. *Comput. Biol. Med.* **124**, 103949 (2020).

519   41.   Liang, W. *et al.* Early triage of critically ill COVID-19 patients using deep learning. *Nat. Commun.* **11**, 3543 (2020).

520   42.   Yadaw, A. S. *et al.* Clinical features of COVID-19 mortality: development and validation of a clinical prediction
521   model. *Lancet Digit. Heal.* **2**, e516–e525 (2020).

522   43.   Wynants, L. *et al.* Prediction models for diagnosis and prognosis of covid-19: Systematic review and critical
523   appraisal. *BMJ* **369**, m1328 (2020).

524   44.   Ciceri, F. *et al.* Decreased in-hospital mortality in patients with COVID-19 pneumonia. *Pathog. Glob. Health* 1–2
525   (2020). doi:10.1080/20477724.2020.1785782

526   45.   J, M., J, O. & C, H. Declining death rate from COVID-19 in hospitals in England. (2020). Available at:
527   https://www.cebm.net/covid-19/declining-death-rate-from-covid-19-in-hospitals-in-england/.

528   46.   Zhang, H. *et al.* Risk prediction for poor outcome and death in hospital in-patients with COVID-19: derivation in
529   Wuhan, China and external validation in London, UK. *medRxiv* 2020.04.28.20082222 (2020).
530   doi:10.1101/2020.04.28.20082222

531
532

Tables and figures

Table 1: Fraction of patients in cohort by sex and comorbitidies.

Sex male	0.593
Other comorbidity	0.315
Hypertension	0.270
Chronic heart disease	0.161
T2 diabetes	0.159
Chronic respiratory disease	0.109
Obesity (clinical)	0.106
Chronic neurological cond.	0.087
Chronic renal disease	0.084
Asthma	0.084
Immunosuppression treatment	0.030
Immunosuppression disease	0.027
Asymptomatic testing	0.021
Chronic liver	0.017
T1 diabetes	0.012
Pregnancy	0.006
Serious mental illness	0.006
Sex unknown	0.002

Table 2: Fraction of patients in cohort by ethnicity.

White British	0.598
Eth. NA	0.134
Eth. unknown	0.102
Other white	0.026
Other Asian	0.024
Other ethn.	0.024
Indian	0.024
Pakistani	0.019
Black African	0.013
Black Caribbean	0.010
Other black	0.006
White Irish	0.004
Other mixed	0.004
Bangladeshi	0.004
White and black Caribbean	0.003
Chinese	0.003
White and black African	0.002
White and Asian	0.002

Figure 1. Correlation heatmap between self-defined ethnicities and pre-existing conditions.
Color shades from blue to red correspond to increasing values of Person correlation
coefficient (white: no correlations are present). NA labels inpatients who did not identify
themselves with any ethnicity.

Table 3. Estimated odd ratios (ORs) from adjusted logistic regressions and importance (*Imp*)
scores of death and intensive-care unit admission (ICUA) outcomes. P values that do not test
significant according to the Benjamini-Hochberg procedure are marked with a dagger(†).

	Death outcome				ICUA outcome			
	OR	**95% CI**	**Pr(>|z|)**	***Imp***	**OR**	**95% CI**	**Pr(>|z|)**	***Imp***
Comorbidities:								
Immunosuppr. disease	1.392	1.1-1.76	0.006	0.25	0.826	0.63-1.07	0.157†	-0.13
T2 diabetes	1.307	1.17-1.46	0.000	0.18	1.018	0.9-1.15	0.778†	-0.05
T1 diabetes	1.228	0.85-1.77	0.275†	0.07	0.414	0.27-0.63	0.000	-1.09
Chronic liver	1.215	0.89-1.64	0.209†	0.11	1.146	0.83-1.58	0.406†	0.00
Chronic respiratory disease	1.188	1.05-1.35	0.008	0.08	0.830	0.72-0.96	0.011	-0.21
Obesity (clinical)	1.163	1.01-1.33	0.030†	0.08	3.371	2.9-3.92	0.000	0.87
Serious mental illness	1.087	0.63-1.82	0.755†	0.04	2.575	1.5-4.46	0.001	0.49
Chronic renal disease	1.081	0.94-1.25	0.284†	0.15	0.672	0.57-0.79	0.000	-0.21
Chronic neurological cond.	1.064	0.93-1.22	0.381†	0.08	0.322	0.27-0.39	0.000	-1.01
Chronic heart disease	1.017	0.91-1.14	0.770†	0.05	0.481	0.42-0.55	0.000	-0.45
Hypertension	1.003	0.91-1.1	0.958†	0.00	1.578	1.42-1.76	0.000	0.30
Other comorbidity	0.871	0.8-0.95	0.003	-0.05	1.314	1.19-1.45	0.000	0.21
Asthma	0.869	0.75-1.01	0.070†	-0.10	1.512	1.29-1.77	0.000	0.25
Ethnicities:								
White and Asian	2.401	0.92-6.11	0.066	0.00	2.451	0.95-6.91	0.073†	0.00
Other black	2.204	1.34-3.61	0.002	0.42	3.583	1.96-7.03	0.000	1.18
White and black Caribbean	1.996	1.03-3.83	0.038	0.00	2.570	1.23-5.84	0.017	0.76
White and black African	1.842	0.78-4.15	0.149†	0.00	3.439	1.33-10.75	0.018	0.61
Indian	1.838	1.42-2.37	0.000	0.41	2.443	1.86-3.23	0.000	0.76
Chinese	1.784	0.85-3.71	0.122†	0.00	10.224	3.92-35.06	0.000	1.85
Pakistani	1.709	1.28-2.28	0.000	0.33	1.158	0.87-1.54	0.314†	0.04
Other mixed	1.584	0.78-3.07	0.187†	0.00	3.069	1.5-6.81	0.003	1.03
Black Caribbean	1.499	1.02-2.2	0.040	0.29	5.247	3.26-8.84	0.000	1.60
Bangladeshi	1.376	0.7-2.61	0.338†	0.00	3.086	1.6-6.32	0.001	1.11
Other Asian	1.265	0.97-1.65	0.084	0.19	3.183	2.41-4.25	0.000	1.01
Other white	1.076	0.83-1.39	0.585†	0.03	2.721	2.09-3.57	0.000	1.01
Eth. unrecorded	0.969	0.86-1.09	0.607†	-0.05	0.160	0.13-0.19	0.000	-1.78
Other eth.	0.966	0.72-1.28	0.809†	0.03	3.711	2.75-5.08	0.000	1.03
Black African	0.922	0.62-1.33	0.672†	-0.04	4.170	2.78-6.46	0.000	1.35
Eth. unknown	0.859	0.75-0.99	0.032†	-0.10	0.770	0.67-0.88	0.000	-0.26
White Irish	0.493	0.25-0.92	0.032†	-0.19	0.933	0.51-1.68	0.818†	0.00
Other:								
Sex unknown	1.900	0.76-4.74	0.165†	0.00	0.395	0.08-1.45	0.205†	0.00
Age (x10 years)	1.560	1.51-1.61	0.000	0.02	0.764	0.74-0.78	0.000	-0.02
Sex male	1.543	1.42-1.68	0.000	0.13	1.735	1.59-1.89	0.000	0.16
Immunosuppr. treatment	1.229	0.98-1.54	0.072†	0.10	1.793	1.41-2.28	0.000	0.55
Admission day	0.795	0.76-0.83	0.000	-0.24	0.666	0.64-0.7	0.000	-0.39
Pregnancy	0.714	0.3-1.52	0.414†	0.00	0.339	0.2-0.57	0.000	-0.19
Asymptomatic testing	0.291	0.18-0.45	0.000	-0.82	0.517	0.35-0.74	0.000	-0.44

Figure 2. Contrasting odd ratios (ORs) of death with ORs of intensive care unit admission
(ICUA). Features are grouped into comorbidities, self-defined ethnicities, and others (top to
bottom). For binary variables, marker sizes are proportional to the frequencies of the
exposure. Error bars are 68% confidence intervals (CIs). Gray and white regions correspond

to discordant and concordant associations. The figure highlights mismatches in the ORs of a
number of variables, e.g., asthma and "other comorbidity" were risk factors for ICUA but
protective for death outcome. Chronic respiratory disease was a risk factor for death but
negatively associated with ICU admission. For most ethnicities the ORs of death and ICUA
were concordant in sign but of different magnitude.

Abbreviations:
Mental ill.: serious mental illness
Resp. dis.: respiratory disease
Neuro. dis.: neurological disease
Immunos. dis.: immunosuppression due to disease
T2D: type-1 diabetes
T1D: type-2 diabetes
Eth. NA: ethnicity unrecorded
Immunos. treat.: immunosuppression due to treatment
Asymp. : asymptomatic – meaning that testing was not due to the presence of COVID-19
symptoms

581 Figure 3. ROC curves (C-statistics) of the logistic regression classifiers over the validation set.
582 Confidence intervals are obtained by means of bootstrapping.

584   Table 4. Variance inflation factors (VIFs) for the logistic regressions. VIF scores are always
585   smaller than two, excluding serious collinearity issues.

	VIF death	VIF ICUA
Age (x10 years)	1.29	1.19
Hypertension	1.26	1.28
Chronic heart disease	1.25	1.21
T2 diabetes	1.19	1.18
Other comorbidity	1.18	1.18
Chronic renal disease	1.15	1.14
Obesity (clinical)	1.13	1.07
Eth. NA	1.12	1.07
Chronic respiratory disease	1.10	1.10
Chronic neurological cond.	1.08	1.04
Admission day	1.07	1.13
Eth. unknown	1.07	1.07
Immunosuppr. treatment	1.06	1.06
Immunosuppr. disease	1.05	1.05
Asthma	1.05	1.05
Other Asian	1.05	1.03
Sex male	1.05	1.03
Indian	1.04	1.03
Pakistani	1.04	1.04
Asymptomatic testing	1.04	1.09
Other ethn.	1.04	1.02
Other white	1.03	1.02
Black African	1.03	1.02
Other black	1.02	1.01
Chronic liver	1.02	1.02
Black Caribbean	1.02	1.01
T1 diabetes	1.02	1.02
Serious mental illness	1.01	1.02
Other mixed	1.01	1.01
White and black Caribbean	1.01	1.01
Sex unknown	1.01	1.01
Bangladeshi	1.01	1.01
Pregnancy	1.01	1.03
White and Asian	1.01	1.01
White and black African	1.01	1.00
Chinese	1.01	1.00

586
587

589
Figure 4. Contrasting Shapley values for impact on death and intensive-care unit admission
ICUA for all variables included in this study. Each marker in the scatter plots corresponds to
an in-patient. Colors from red to blue indicate the value of the underlying variable (in binary

variables, red color means feature is present, blue otherwise; in age feature, red to blue

shades correspond to old to young ages; in admission day, red to blue shades correspond to

early to late dates). The explanation models assigned a concordant (discordant) impact on

death and ICUA to the patients in the white (grey) regions. The scatter plots expose not only

the importance of a potential risk factor but also its range of effects over the cohort. All

patients with immunosuppression disease, type-2 diabetes, liver and respiratory disease,

and Pakistani self-defined ethnicity had positive Shapley values from death, with impact on

ICU ranging from negative to positive values, thus suggesting that these conditions were

always leaning towards death but sometimes not consistently towards ICUA. Conversely

hypertension always have positive impact on ICUA whilst can either have positive or

negative impact on death for different patients. The Shapley values for death for many

features appear clustered (T1 diabetes, chronic liver, neurological, and hearth disease

comorbidities), thus suggesting the presence of different groups under the same labels with

different effect on patient health. Inspection of the age pattern suggests the presence of a

group of young patients (blue markers) with negative impact on both age and ICUA

outcome, old-age patients with positive impact on death and negative impact on ICUA

outcome, and intermediate-age patients with impacts negative on death and positive on

ICUA outcome.

For abbreviations, see the caption of Figure 2.

Figure 5. SHAP importance scores from the explaination model for GBDT vs logarithm of
odd-rations (ORs) from logistic regression for death (A) and intensive-care unit (ICU)
admission (B). Each point represents a feature (see Table 3). Red markers correspond to the
features whose association with the outcome was not significant according to the logistic
regression . The x-axis errorbars comprise 68% confidence intervals. The SHAP importance
Imp allows us to assess to what extent a feature contributes to the GBDT prediction. This
plot shows that these are consistent with the well-known logistic regression coefficients,
despite the underlying models used to generate these two quantities are fundamentally
different.

626
627 Figure 6. A-B) Partial dependence plots (PDPs) and probability of death predicted by GBDT
628 for each patient in training set. C-D) SHAP main effect for age and admission date. These
629 effects can be ascribed to the age/admission date alone, regardless of their covariates. The
630 strong pattern in the main effect for admission date highlights the importance of
631 incorporating timing in predictive models.

632
633

634
635   Figure 7. A-B) Partial dependence plots (PDPs) and probability of intensive-care unit
636   admission predicted by GBDT for each patient in training set. C-D) SHAP main effect for age
637   and admission date.